Optimal clinical trial designs for immune-based therapies in persistent viral infections
AUTOR(ES)
Smith, Kendall A
FONTE
BioMed Central
RESUMO
There is now effective therapy for infection by the Human Immunodeficiency Virus (HIV), but there is no cure. Consequently, antiviral drugs must be administered continuously to suppress viral replication. Recently, a large phase III international immune-based therapy trial was discontinued because it is difficult to measure clinical endpoints while antivirals are administered. Since the immune system has evolved under the selective force of microbial infections, the immune reaction is antiviral. This commentary explores the rationale of using "Diagnostic Treatment Interruptions" of antiviral therapies to determine efficacies of immune-based therapies.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=149407Documentos Relacionados
- Multiple cytokine expression profiles reveal immune-based differences in occult hepatitis B genotype H-infected Mexican Nahua patients
- Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
- Characterization of Persistent Modoc Viral Infections in Syrian Hamsters
- Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections
- Clinical trial of cefonicid for treatment of skin infections.